ALN-6400 (PLG) Investigational plasminogen-silencing RNAi therapy in Phase 2 development for hereditary hemorrhagic telangiectasia and von Willebrand disease, targeting abnormal bleeding.
Visit productCosigns Received
Be the first Cosign
Put your name behind ALN-6400 (PLG).
Add it to your Products I use list and share why you use it.